Researchers in Boston are set to co-lead a long-term study on the aging brain and factors that make individuals more vulnerable to neural injury and cognitive decline.
The team’s work will emphasize the role of specialized MRI techniques capable of detecting subtle changes around tumors with the help of pH-based imaging.
Using a virtual reality headset, the system, dubbed AR-VIU (augmented real-time volumetric imaging in ultrasound), creates a 3D rendering of anatomy based on 2D ultrasound images.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Experts involved in its development are confident the agent has the potential to overcome shortcomings associated with conventional oral agents currently on the market.
Extravascular ICDs were developed to avoid complications such as vascular injuries, lead fractures and lead infections. Although rare, these issues can cause serious, life-threatening complications for patients.
The CGuard Prime carotid stent system from InspireMD was approved by the FDA in 2025. These data confirm the device's ability to reduce a patient's stroke risk during treatment.
Cardiology has been shifting from reactionary treatment strategies to a greater emphasis on prevention. This is an especially important trend in heart failure, which is associated with high costs and rising hospitalization rates.
